← FDA DRUG APPROVALS

FDA ANDA · ANDA215654

DEXAMETHASONE SODIUM PHOSPHATE

Sponsor: GLAND

APPLICATION
ANDA215654
TYPE
ANDA
ORIGINAL APPROVAL
2021-08-04
LATEST ACTION
2025-04-03
ROUTE
INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRAVENOUS, SOFT TISSUE, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

DEXAMETHASONE SODIUM PHOSPHATEPrescription
DEXAMETHASONE SODIUM PHOSPHATE EQ 4MG PHOSPHATE/ML · INJECTABLE · INJECTION
DEXAMETHASONE SODIUM PHOSPHATEPrescription
DEXAMETHASONE SODIUM PHOSPHATE EQ 10MG PHOSPHATE/ML · INJECTABLE · INJECTION

Approval history

2025-04-03Labeling · Supplement 4 · standardAP
2024-06-05Labeling · Supplement 3 · standardAP
2021-08-04UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →